Acurx Pharmaceuticals, Inc. (ACXP) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-22

Key Insights

CFO Robert G. Shawah received a grant of 25,900 stock options on April 20, 2026, with an exercise price of $2.36 per share, indicating the company's current valuation and potential confidence in future performance.
The options vest over 36 months in equal monthly installments, demonstrating a standard long-term incentive structure designed to retain executive talent and align management interests with shareholder value over a multi-year period.
This is a non-cash compensation grant rather than an insider purchase, which suggests no significant capital commitment from management but does reflect the company's equity-based compensation practices during this period.
The relatively modest option grant size and exercise price point suggest ACXP may be a smaller biotech firm managing cash carefully while using equity to compensate executives.

Want the newest filings?

This analysis covers the filing from 2026-04-22. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-22

President and CEO David P. Luci received a stock option grant of 37,100 shares at an exercise price of $2.36, vesting over 36 months in equal monthly installments, indicating continued executive compensation and potential confidence in company direction.
The vesting schedule of monthly installments over 3 years is a standard retention mechanism that aligns executive interests with long-term shareholder value, though provides no immediate indication of insider's near-term price expectations.
As a company officer and director, this grant represents routine equity compensation rather than discretionary open-market buying, which would be a stronger signal of insider confidence in the stock's valuation.

Filed: 2026-04-22

Director Robert J. DeLuccia received a grant of 37,100 stock options on April 20, 2026, with an exercise price of $2.36 per share, suggesting the company's stock was trading near or around this price level at grant time.
The options vest monthly over 36 months (3-year vesting schedule) with a 10-year expiration, indicating a typical equity compensation structure designed for long-term retention and alignment with company performance.
As a Director with this significant option grant, DeLuccia maintains direct beneficial ownership exposure to the company, though the options represent dilutive potential rather than immediate ownership stakes.

Filed: 2026-04-22

Director Joseph C. Scodari received a stock option grant of 2,150 shares at $2.36 exercise price on April 20, 2026, vesting one year later on April 20, 2027, consistent with standard director compensation practices.
This is a routine equity grant to a board member rather than open market purchases, indicating no insider confidence signal regarding undervaluation of the stock at current levels.
The filing shows Scodari's only beneficial ownership position following this transaction is the 2,150 option shares, suggesting minimal existing stake in ACXP or recent liquidation of holdings.

Filed: 2026-04-22

Director Thomas L. Harrison received a stock option grant of 2,150 shares at an exercise price of $2.36 per share on 04/20/2026, vesting over one year, indicating board-level compensation rather than significant insider conviction.
The option grant is relatively modest in size and represents standard director compensation under the company's Director Compensation Policy rather than an opportunistic insider purchase at current market prices.
No concurrent cash transactions or dispositions were reported, and the option vests April 20, 2027, suggesting the director has limited near-term incentive to accumulate additional shares at the current valuation.

Filed: 2026-04-22

Director James J. Donohue received a stock option grant of 2,150 shares at an exercise price of $2.36, awarded on 04/20/2026 as part of standard board compensation, with a one-year vesting schedule expiring in 2036.
This is a routine equity grant to a board member rather than an insider buy or sell transaction, indicating normal governance practices rather than market-driven trading decisions.
The grant size and structure are consistent with director compensation policies and do not suggest confidence signals about future stock performance, as these awards are automatic and formulaic.

Filed: 2026-04-22

Director Jack H. Dean received a stock option grant of 2,150 shares at $2.36 exercise price on 04/20/2026, vesting one year later on 04/20/2027, representing standard board compensation rather than open market transactions.
This is a routine director compensation grant pursuant to the company's Director Compensation Policy, indicating normal corporate governance practices with no significant insider buying or selling activity.
The option grant amount and exercise price suggest modest equity incentives for board service, which is typical for smaller pharmaceutical companies but provides limited insight into management's confidence in future stock performance.

Filed: 2026-04-22

Director Carl Sailer received a stock option grant of 2,150 shares at $2.36 exercise price on 04/20/2026, vesting one year from grant date, indicating routine director compensation rather than performance-based incentive.
The option grant represents standard board service compensation under the company's Director Compensation Policy, suggesting no material change in insider sentiment or confidence levels.
With a one-year vesting schedule and ten-year expiration, this grant is typical for director retention rather than reflecting significant insider buying conviction or concerns about stock valuation.
No concurrent open market purchases or dispositions were reported, indicating this was purely compensation-related without additional voluntary investment by the director.

Other reports for Acurx Pharmaceuticals, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.